Omacetaxine Mepesuccinate

10月17日，普洛药业科学顾问委员会（SAB）2026年会暨国际前沿化学与生物医药创新论坛在横店举办，普洛药业股份有限公司参会人员与来自国内外化学、生物医药领域的专家，创新药企业代表、资本市场代表，以及产业合作伙伴通过交流分享，探索新药创新、研发与产业转化的新机遇，进一步促进学术界与产业界的合作。 中国科学院院士、复旦大学教授麻生明，美国国家科学院院士、美国文理科学院院士Phil S. Baran，北京大学博雅特聘教授雷晓光博士，百济神州高级副总裁王志伟博士，以及横店集团董事、副总裁吴兴，横店集团助理总裁、普洛药业董事长祝方猛，普洛药业总经理何春等出席活动。会议由普洛药业助理总经理、SAB秘书长詹威强博士主持。 普洛药业深耕医药产业30余年，是国内医药小分子CDMO企业与特色原料药头部企业。近年来，公司坚定实施“做精原料、做强CDMO、做好药品、拓展医美”的发展战略，在2022年成立科学顾问委员会，相继聘请麻生明院士、郑裕国院士、Phil S. Baran院士、李昂教授、徐建鸿教授、雷晓光教授、杜争鸣博士等全球生物医药科学领域的领军人物，在化学合成、合成生物学、多肽与核酸等前沿方向为企业发展把脉定向，并不断强化质量体系和国际化运营能力，致力成为创新者背后“快且稳”的伙伴。在科顾委的引领下，公司已搭建并完善流体化学、合成生物学及酶催化、多肽等11个技术平台。今年8月，公司荣获2026年沙利文全球CDMO年度公司奖，标志着企业在解决高技术壁垒工艺难题、支持全球药企应对供应链风险等方面，赢得了国际市场的广泛信赖。 当前，创新药竞争已从单一研发突破延伸至工艺开发、工程放大、质量合规、供应链交付与商业化落地的全链条。正是在这一背景下，普洛药业以科顾委年会为契机举办国际前沿化学与生物医药创新论坛，通过专家报告、圆桌对话等形式，共研前沿技术、共破产业难题、共筑产业生态。 麻生明 博士中国科学院院士、复旦大学教授 中国科学院院士、复旦大学教授麻生明博士以《ATA Dating with Aerobic Oxidations》为主题，介绍了他深究多年ATA反应及绿色氧化，分享了以简单易得的原料构建结构复杂1,3-二取代丙二烯的高效方法，并分享了他的方法在复杂天然产物、生物活性分子和药物中间体合成应用成果，展现了工业化应用潜力，以及对精细化工和药物研发的价值。 Phil S. Baran 博士美国国家科学院院士、美国文理科学院院士 美国国家科学院院士、美国文理科学院院士Phil S. Baran博士以《Simplifying Synthesis through Radical Cross-Coupling》为主题，以他一贯的逻辑清晰充满激情的风格，通过分析新药研发中的关键合成瓶颈和核心难点，介绍了自由基交叉偶联在迅速构建复杂候选药物分子中的应用。他使用简答易得的磺酰肼作为理想自由基前体的研究，通过镍催化可控自由基偶联反应，实现了传统方法很难做到的C-C键构建，不仅操作简单条件温和，更提供了灵活多变的逆合成战略，为药物研发和工艺开发提供全新的视角和有效的方法论。 雷晓光 博士北京大学化学学院博雅特聘教授 北京大学博雅特聘教授雷晓光博士以《Frontiers in Biocatalysis and Drug Innovation》为主题，围绕“生物催化驱动的变革性药物合成”，介绍了天然产物生物合成与酶催化在药物合成中的前沿进展。报告分享了紫杉醇关键中间体、高三尖杉酯碱等天然产物生物合成路径解析，以及通过定向进化和蛋白质工程创制新酶的工作。他还报告了酶催化酰胺键合成的最新突破，解决了制药合成中应用做多的反应的核心问题，充分展示了生物催化在绿色制药和产业应用中的潜力。 王志伟 博士百济神州高级副总裁 百济神州高级副总裁王志伟博士以《The story of Brukinsa: from bench to bedside》为主题，以泽布替尼为例，分享了创新药从实验室发现到临床和国际化上市的全过程。报告回顾了BTK抑制剂的设计思路，围绕提高靶点占有率、持续抑制和选择性等目标开展结构优化，分享了新药研发过程中的策略，方法，以及未来新药研发中与CDMO合作协同的战略作用。目前泽布替尼在疗效和安全性方面展现出优势，并通过头对头研究验证竞争力。 来自MNC全球外部制造总监李劼博士，泽璟制药首席科学官吕彬华博士，百济神州CMC高级总监刘军涛博士，Structure生物高级副总裁姜兴龙博士等客户代表，与普洛药业高级副总经理、CDMO事业部总经理蔡磊，普洛药业CTO肖毅博士围绕“赋能·链接·交付，创新药生态中的CDMO力量”这一主题，从不同类型创新药企业的实际需求出发，就CDMO如何在研发、工艺开发、技术转移和商业化交付等环节更好地赋能客户，创造价值进行了深入交流。浙商证券医药首席分析师郭双喜博士主持圆桌对话。 普洛药业负责人在交流中介绍了公司在人才体系建设、流体化学和生物催化等技术平台方面的布局，以及面向早期项目速度和后期CMC合规的完整服务能力，并努力成为客户“外部的CMC团队”，覆盖从毒理、临床到上市各阶段，并在商业化产能建设、全球技术转移和PPQ成功率等方面提前布局，帮助客户在成本可控、时间更短的前提下实现稳定交付。 活动期间，与会嘉宾还到普洛药业CDMO研发及生产基地走访参观，实地了解企业研发和生产运营情况。 Apeloa Pharmaceutical Hosts 2026 SAB Annual Meeting & International Forum on Frontiers in Chemistry and Biopharmaceutical Innovation in Hengdian Hengdian, China, October 17, 2026 — Apeloa Pharmaceutical Co., Ltd. today convened its 2026 Scientific Advisory Board (SAB) Annual Meeting & International Forum on Frontiers in Chemistry and Biopharmaceutical Innovation in Hengdian, Zhejiang Province. The two-day gathering brought together leading scientists in chemistry and biomedical research from China and abroad, representatives from innovative drug companies, capital market participants, and industry partners to explore new opportunities in drug discovery, development, and commercialization — and to strengthen collaboration between academia and industry. Among the distinguished attendees were Dr. Shengming Ma, Member of the Chinese Academy of Sciences and Department of Chemistry Fudan University; Dr. Phil S. Baran, Member of the U.S. National Academy of Sciences and the American Academy of Arts and Sciences; Dr. Xiaoguang Lei, Boya Distinguished Professor, College of Chem. & Mol. Eng., Peking University; Dr. Zhiwei Wang, Senior Vice President at BeOne Medicines; John Wu, Director and Vice President of Hengdian Group; Brian Zhu, Assistant President of Hengdian Group and Chairman of Apeloa Pharmaceutical; and  Chun He, General Manager of Apeloa Pharmaceutical. The event was chaired by Dr. Steve Zhan, Assistant General Manager of Apeloa Pharmaceutical and Secretary-General of the SAB. With more than 30 years of experience in the pharmaceutical industry, Apeloa has established itself as a leading player in both small-molecule CDMO services and specialty active pharmaceutical ingredients (APIs) in China. Guided by its strategy of "Global API Leader, CDMO Excellence, High-quality & Affordable Medicine, Expanding Aesthetic & Care Ingredients" the company established its Scientific Advisory Board in 2022. The SAB brings together some of the world's most influential minds in biomedical science — including Dr. Shengming Ma, Dr. Yuguo Zheng, Dr. Phil S. Baran, Dr. Ang Li, Dr. Jianhong Xu, Dr. Xiaoguang Lei, and Dr. Zhengming Du — providing strategic direction in cutting-edge fields such as chemical synthesis, synthetic biology, and peptides and nucleic acids. Under the guidance of the SAB, Apeloa has built and refined 11 technology platforms spanning flow chemistry, synthetic biology and enzymatic catalysis, and peptide technologies. In August this year, Apeloa received the 2026 Frost & Sullivan Global CDMO Company of the Year Award — a recognition of the company's international standing in solving high-barrier process challenges and supporting global pharmaceutical companies in managing supply chain risks. The award underscores Apeloa's ambition to be a partner that is "fast and dependable" behind every innovator. Competition in the innovative drug landscape has evolved well beyond breakthroughs in R&D alone. Today, success depends on the entire value chain — from process development and scale-up engineering to quality compliance, supply chain delivery, and commercialization. Against this backdrop, Apeloa leveraged its SAB annual meeting as a platform for the international forum, where keynote presentations and roundtable discussions fostered open exchange on frontier technologies, collective solutions to industry challenges, and the building of a robust industrial ecosystem. Keynote Lecture Dr. Shengming Ma Member, Chinese Academy of Sciences; Department of Chemistry Fudan University Dr. Shengming Ma, Chinese Academy of Sciences and Department of Chemistry Fudan University, delivered a presentation titled "ATA Dating with Aerobic Oxidations." Drawing on decades of dedicated research, Prof. Ma introduced efficient strategies for constructing structurally complex 1,3-disubstituted allenes from simple, readily available starting materials through ATA reactions combined with green aerobic oxidation. He also showcased the successful application of these methods in the total synthesis of complex natural products, biologically active molecules, and pharmaceutical intermediates—underscoring significant potential for industrial-scale application and delivering tangible value for the fine chemical and pharmaceutical industries. Dr. Phil S. Baran Member, The U.S. National Academy of Sciences; Member, American Academy of Arts and Sciences Dr. Phil S. Baran, Member of the U.S. National Academy of Sciences and the American Academy of Arts and Sciences, presented "Simplifying Synthesis through Radical Cross-Coupling." In his signature clear and passionate style, Dr. Baran dissected the key synthetic bottlenecks and core challenges in modern drug discovery. He introduced the use of simple, inexpensive sulfonyl hydrazides as ideal radical precursors, demonstrating how nickel-catalyzed controlled radical cross-coupling enables the construction of C–C bonds that conventional methods struggle to achieve. Beyond being operationally simple and mild in reaction conditions, this approach offers a flexible and versatile retrosynthetic strategy, providing fresh perspectives and practical methodologies for drug R&D and process development. Dr. Xiaoguang Lei Boya Distinguished Professor, College of Chem. & Mol. Eng., Peking University Dr. Xiaoguang Lei, Boya Distinguished Professor, College of Chem. & Mol. Eng., Peking University, spoke on "Frontiers in Biocatalysis and Drug Innovation," focusing on "biocatalysis-driven transformative drug synthesis." He presented cutting-edge advances in natural product biosynthesis and enzyme catalysis, including the elucidation of biosynthetic pathways for key taxol (paclitaxel) intermediates and homoharringtonine, as well as the creation of novel enzymes through directed evolution and protein engineering. A highlight of the talk was the latest breakthrough in enzyme-catalyzed amide bond formation—addressing one of the most frequently used yet long-standing challenges in pharmaceutical synthesis—and demonstrating the immense potential of biocatalysis in green manufacturing and industrial applications. Dr. Zhiwei Wang SVP, BeOne Medicines Dr. Zhiwei Wang, Senior Vice President at BeOne Medicines, shared the story of Brukinsa (zanubrutinib) in his presentation "The Story of Brukinsa: From Bench to Bedside," Using zanubrutinib as a case study, Dr. Wang walked the audience through the full journey of an innovative drug—from laboratory discovery to clinical development and global market approval. He revisited the design rationale behind this BTK inhibitor, detailing the structural optimization driven by the goals of improved target occupancy, sustained inhibition, and enhanced selectivity. He also shared strategic insights from the drug development process and the increasingly important role of CDMO collaboration in future R&D. Today, zanubrutinib has demonstrated clear advantages in both efficacy and safety, validated through head-to-head clinical trials. Panel Discussion A roundtable discussion titled "Enabling, Connecting, Delivering: The Power of CDMO in the Innovative Drug Ecosystem" brought together customer representatives and Apeloa's senior leadership for an in-depth exchange on how CDMOs can better empower their clients and create value across R&D, process development, technology transfer, and commercial delivery. The panel featured Dr. Jie Li, Global Director of External Manufacturing at a leading multinational pharmaceutical company; Dr. Binhua Lv, Chief Scientific Officer at Zelgen Biopharmaceuticals; Dr. Juntao Liu, Senior Director of CMC at BeOne; and Dr. Xinglong Jiang, Senior Vice President at Structure Bio — alongside Mr. George Cai, Senior Deputy General Manager of Apeloa Pharmaceutical and General Manager of the CDMO Business Unit, and Dr. Yi Hsiao, Chief Technology Officer of Apeloa Pharmaceutical. The discussion was moderated by Dr. Shuangxi Guo, Chief Pharmaceutical Analyst at Zheshang Securities. Drawing on the real-world needs of different types of innovative drug companies, the panel explored what clients truly value at each stage of development — and where a CDMO partner can make the decisive difference. Speaking at the session, Apeloa's leadership outlined the company's comprehensive capabilities: a robust talent development system, technology platforms in flow chemistry and biocatalysis, and an integrated service offering that balances speed for early-stage projects with CMC compliance for late-stage development. Apeloa's ambition is to serve as its clients' "external CMC team" — supporting programs from toxicology studies and clinical trials through to commercial launch. Looking ahead, the company has made proactive investments in commercial-scale manufacturing capacity, global technology transfer capabilities, and PPQ (Process Performance Qualification) success rates — all designed to help clients achieve stable, reliable delivery at controlled cost and with shorter timelines. Site Tour As part of the event program, attendees also visited Apeloa's CDMO R&D and manufacturing site, where they gained firsthand insight into the company's research, development, and production operations. 出 品 人  ：祝方猛 主     编  ：聂文彬 往期精彩推荐 倒计时5天！普洛药业SAB 2026年会暨国际前沿化学与生物医药创新论坛与您相约横店 普洛药业CDMO再+1！海纳安®原料药获批，创新药全链条服务能力再升级 普洛药业亮相 CPHI Milan 2026，展示一体化医药解决方案 斩获多项荣誉，共话产业未来｜普洛药业亮相第八届CMC-China中国制药工业博览会  立 即 扫 码 关 注  普洛大药房旗舰店 @ 京 东